Nitric oxide accelerates interleukin-13 cytotoxin-mediated regression in head and neck cancer animal model

Clinical Cancer Research

Volumn 10, Issue 15, 2004, Pages 5264-5270

  Kawakami, Koji ^a   Kawakami, Mariko ^a   Puri, Raj K ^a  

^a Division of Viral Products   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIN; HYBRID PROTEIN; INTERLEUKIN 13; INTERLEUKIN 13 RECEPTOR; N(G) METHYLARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; RECOMBINANT PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RECURRENCE; CANCER REGRESSION; CELL FUNCTION; CONTROLLED STUDY; DISEASE MODEL; DRUG POTENCY; EFFECTOR CELL; GENE OVEREXPRESSION; GLIOBLASTOMA; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; KAPOSI SARCOMA; KIDNEY CARCINOMA; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; SOLID TUMOR; STATISTICAL SIGNIFICANCE; WESTERN BLOTTING; XENOGRAFT;

ANIMALS; BLOTTING, WESTERN; CELL LINE, TUMOR; CYTOTOXINS; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; ENZYME INHIBITORS; EXOTOXINS; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOTOXINS; INTERLEUKIN-13; MACROPHAGES; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS; NITRIC OXIDE; OMEGA-N-METHYLARGININE; RECOMBINANT FUSION PROTEINS;

EID: 4143059158     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0314     Document Type: Article

References (47)

1. Debinski W, Obiri NI, Powers SK, Pastan I, Puri RK. Human glioma cells overexpress receptor for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and Pseudomonas exotoxin. Clin Cancer Res 1995;1:1253-8.
2. Joshi BH, Plautz GE, Puri RK. IL-13 receptor α chain: a novel tumor associated transmembrane protein in primary explants of human malignant gliomas. Cancer Res 2000;60:1168-72.
3. Liu H, Jacobs BS, Liu J, et al. Interleukin-13 sensitivity and receptor phenotypes of human glial cell lines: non-neoplastic glia and low-grade astrocytoma differ from malignant glioma. Cancer Immunol Immunother 2000;49:319-24.
4. Bernard J, Treton D, Vermot-Desroches C, et al. Expression of interleukin 13 receptor in glioma and renal cell carcinoma: IL13Rα2 as a decoy receptor for IL13. Lab Investig 2001;81:1223-31.
5. Kawakami M, Leland P, Kawakami K, Puri RK. Mutation and functional analysis of IL-13 receptors in human malignant glioma cells. Oncol Res 2001;12:459-67.
6. Obiri NI, Debinski W, Leonard WJ, Puri RK. Receptor for interleukin 13: interaction with interleukin 4 by a mechanism that does not involve the common γ chain shared by receptors for interleukins 2, 4, 7, 9, and 15. J Biol Chem 1995;270:8797-804.
7. Husain SR, Obiri NI, Gill P, et al. Receptor for interleukin 13 on AIDS-associated Kaposi's sarcoma cells serves as a new target for a potent Pseudomonas exotoxin-based chimeric toxin protein. Clin Cancer Res 1997;3:151-6.
8. Maini A, Hillman G, Haas GP, et al. Interleukin-13 receptors on human prostate carcinoma cell lines represent a novel target for a chimeric protein composed of IL-13 and a mutated form of Pseudomonas exotoxin. J Urol 1997;158:948-53.
9. Murata T, Obiri NI, Puri RK. Human ovarian-carcinoma cell lines express IL-4 and IL-13 receptors: comparison between IL-4- and IL-13-induced signal transduction. Int J Cancer 1997;70:230-40.
10. Joshi BH, Kawakami K, Leland P, Puri RK. Heterogeneity of interleukin-13 receptor expression and subunit structure in squamous cell carcinoma of head and neck: differential sensitivity to a chimeric fusion protein comprised of interleukin-13 and a mutated form of Pseudomonas exotoxin. Clin Cancer Res 2002;8:1948-56.
11. Kawakami M, Kawakami K, Kasperbauer JL, et al. Interleukin-13 receptor α2 chain in human head and neck cancer serves as a unique diagnostic marker. Clin Cancer Res 2003;9:6381-8.
12. Caput D, Laurent P, Kaghad M, et al. Cloning and characterization of a specific interleukin (IL)-13 binding protein structurally related to the IL-5 receptor α chain. J Biol Chem 1996;271:16921-6.
13. Donaldson DD, Whitters MJ, Fitz LJ, et al. The murine IL-13 receptor α2: molecular cloning, characterization, and comparison with murine IL-13 receptor α1. J Immunol 1998;161:2317-24.
14. Kawakami K, Taguchi J, Murata T, Puri RK. The interleukin-13 receptor α2 chain: an essential component for binding and internalization but not for interleukin-13-induced signal transduction through the STAT6 pathway. Blood 2001;97:2673-9.
15. Terabe M, Matsui S, Noben-Trauth N, et al. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat Immunol 2000;1:515-20.
16. Kawakami K, Kawakami M, Snoy PJ, Husain SR, Puri RK. In vivo over-expression of IL-13 receptor α2 chain inhibits tumorigenicity of human breast and pancreatic tumors in immunodeficient mice. J Exp Med 2001;194:1743-54.
17. Kawakami K, Puri RK. Interleukin 13 and cancer. In: Brombacher F, editor. Interleukin-13. Georgetown, TX: Landes Bioscience; 2003. p. 65-78.
18. Debinski W, Obiri NI, Pastan I, Puri RK. A novel chimeric protein composed of interleukin 13 and Pseudomonas exotoxin is highly cytotoxic to human carcinoma cells expressing receptors for interleukin 13 and interleukin 4. J Biol Chem 1995;270:16775-80.
19. Husain SR, Joshi BH, Puri RK. Interleukin-13 receptor as a unique target for anti-glioblastoma therapy. Int J Cancer 2001;92:168-75.
20. Husain SR, Puri RK. Interleukin-13 fusion cytotoxin as a potent targeted agent for AIDS-Kaposi's sarcoma xenograft. Blood 2000;95:3506-13.
21. Kawakami K, Kawakami M, Joshi BH, Puri RK. Interleukin-13 receptor-targeted cancer therapy in an immunodeficient animal model of human head and neck cancer. Cancer Res 2001;61:6194-200.
22. Kawakami K, Husain SR, Kawakami M, Puri RK. Improved antitumor activity and safety of interleukin-13 receptor targeted cytotoxin by systemic continuous administration in head and neck cancer xenograft model. Mol Med 2002;8:487-92.
23. Kawakami M, Kawakami K, Puri RK. Apoptotic pathways of cell death induced by an interleukin-13 receptor-targeted recombinant cytotoxin in head and neck cancer cells. Cancer Immunol Immunother 2002;50:691-700.
24. Kawakami M, Kawakami K, Puri RK. Tumor regression mechanisms by interleukin-13 receptor-targeted cancer therapy involve apoptotic pathways. Int J Cancer 2003;103:45-52.
25. Prados M, Lang F, Strauss L, et al. Pre and post-resection interstitial infusions of IL13-PE38QQR cytotoxin: Phase I study in recurrent respectable malignant glioma. First Quadrennial Meeting of World Federation of Neuro-Oncology; 2001 Nov 15-17; Washington, DC. p. 15-7.
26. Weingart J, Strauss LC, Grossman SA, et al. Phase I/II study: intratumoral infusion of IL13-PE38QQR cytotoxin for recurrent supratentorial malignant glioma. Neuro-Oncology 2002;4:379.
27. Ram Z, Barnett G, Vogelbaum M, et al. Pre-operative infusion of IL13-PE38QQR cytotoxin by convection-enhanced delivery (CED) in recurrent malignant glioma: a phase I/II study (abstract). American Society of Clinical Oncology annual meeting, Chicago, IL, May 30-June 2, 2003.
28. MacMicking J, Xie Q, Nathan C. Nitric oxide and macrophage function. Annu Rev Immunol 1997;15:323-50.
29. Bal-Price A, Brown GC. Nitric-oxide-induced necrosis and apoptosis in PC12 cells mediated by mitochondria. J Neurochem 2000;75:1455-64.
30. Yim C-Y, McGregor JR, Kwon O-D, et al. Nitric oxide synthesis contributes to IL-2-induced antitumor responses against intraperitoneal Meth A tumor. J Immunol 1995;155:4382-90.
31. Zhang F, Lu W, Dong Z. Tumor-infiltrating macrophages are involved in suppressing growth and metastasis of human prostate cancer cells by IFN-β gene therapy in nude mice. Clin Cancer Res 2002;8:2942-51.
32. Xie K, Huang S. Contribution of nitric oxide-mediated apoptosis to cancer metastasis inefficiency. Free Radic Biol Med 2003;15:969-86.
33. Bastian NR, Yim C-Y, Hibbs JB Jr, Samlowski WE. Induction of iron-derived EPR signals in murine cancers by nitric oxide J Biol Chem 1994;269:5127-31.
34. Farias-Eisner R, Sherman MP, Aeberhard E, Chaudhuri G. Nitric oxide is an important mediator for tumoricidal activity in vivo. Proc Natl Acad Sci USA 1994;91:9407-11.
35. Rutschman R, Lang R, Hesse M, Ihle JN, Wynn TA, Murray PJ. Stat6-dependent substrate depletion regulates nitric oxide production. J Immunol 2001;166:2173-7.
36. Salvucci O, Carsana M, Bersani I, Tragni G, Anichini A. Anti-apoptotic role of endogenous nitric oxide in human melanoma cells. Cancer Res 2001;61:318-26.
37. Yang T, Witham TF, Villa L, et al. Glioma-associated hyaluronan induces apoptosis in dendritic cells via inducible nitric oxide synthase: implications for the use of dendritic cells for therapy of gliomas. Cancer Res 2002;62:2583-91.
38. Das T, Sa G, Chattopadhyay S, Ray PK. Protein A-induced apoptosis of cancer cells is effected by soluble immune mediators. Cancer Immunol Immunother 2002;51:376-80.
39. Kawakami K, Tsukuda M, Mizuno H, Nishimura G, Ishii A, Hamajima K. Alteration of the Bcl-2/Bax status on head and neck cancer cell lines by chemotherapeutic agents. Anticancer Res 1999;19:3927-32.
40. + T cells in vivo. Proc Natl Acad Sci USA 1994;91:3077-81.
41. Kawakami K, Kawakami M, Puri RK. Interleukin-13 receptor-targeted cytotoxin cancer therapy leads to complete eradication of tumors with the aid of phagocytic cells in nude mice model of human cancer. J Immunol 2002;169:7119-26.
42. Durect Corporation. Technical information manual, ALZET osmotic pumps. Cupertino, CA: Durect Corporation; 2000. p. 1.
43. Kawakami M, Kawakami K, Puri RK. Intratumoral administration of interleukin 13 receptor-targeted cytotoxin induces apoptotic cell death in human malignant glioma tumor xenografts. Mol Cancer Ther 2002;1:999-1007.
44. Johansson AC, Hegardt P, Janelidze S, Visse E, Widegren B, Siesjo P. Enhanced expression of iNOS intratumorally and at the immunization site after immunization with IFNγ-secreting rat glioma cells. J Neuroimmunol 2002;123:135-43.
45. Chen Y-K, Hsue S-S, Lin L-M. Increased expression of inducible nitric oxide synthase for human buccal squamous cell carcinomas: immunohistochemical, RT-PCR and in situ RT-PCR studies. Head Neck 2002;24:925-32.
46. Kawakami K, Kawakami M, Puri RK. Specifically targeted killing of interleukin-13 receptor-expressing breast cancer by IL-13 fusion cytotoxin in animal model of human disease. Mol Cancer Ther 2004;3:137-47.
47. Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, Oldfield EH. Convection-enhanced delivery to macromolecules in the brain. Proc Natl Acad Sci USA 1994;91:2076-80.